IP Library › Granted Patent US 12,606,639
Granted Patent B2
US 12,606,639 · App. 19/213,402 · Granted Apr 21, 2026

Antigen binding proteins

Inventors: Erding Hu (Collegeville, PA); Matthew Gardener (Stevenage, GB)
Assignee: GlaxoSmith Kline Intellectual Property Development Limited
C07K16/40A61P13/12C12Y304/24079A61K2039/505C07K2317/33C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,639
App. No.
19/213,402
Granted
Apr 21, 2026
Kind
B2
Abstract

The present disclosure relates to antigen binding proteins. More particularly the present disclosure relates to pregnancy associated plasma protein-A (PAPPA) binding proteins, even more particularly PAPPA binding proteins that inhibit cleavage of insulin like growth factor binding protein-2 (IGFBP-2), insulin like growth factor binding protein-4 (IGFBP-4) and insulin like growth factor binding protein-5 (IGFBP-5). The present disclosure further relates to the use of said binding proteins in medicine.

Claims (22)

1 . A PAPPA binding protein comprising a variable heavy chain (VH) region comprising three heavy chain CDR sequences, CDRH1, CDRH2, and CDRH3, and a variable light chain (VL) region comprising three light chain CDR sequences, CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises SEQ ID NO: 107; CDRH2 comprises SEQ ID NO: 108; CDRH3 comprises SEQ ID NO: 109; CDRL1 comprises SEQ ID NO: 113; CDRL2 comprises SEQ ID NO: 114; and CDRL3 comprises SEQ ID NO: 115.

2 . The PAPPA binding protein of claim 1 , wherein said binding protein comprises a VH region that is 100% identical to SEQ ID NO: 105.

3 . The PAPPA binding protein of claim 1 , wherein said binding protein comprises a VL region that is 100% identical to SEQ ID NO: 111.

4 . The PAPPA binding protein of claim 1 , wherein said binding protein comprises a VH region that is 100% identical to SEQ ID NO: 105 and a VL region that is 100% identical to SEQ ID NO: 111.

5 . The PAPPA binding protein of claim 1 , wherein said binding protein comprises a heavy chain constant region as shown in SEQ ID NO: 17 and a light chain constant region as shown in SEQ ID NO: 19.

6 . The PAPPA binding protein of claim 4 , wherein said binding protein comprises a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is shown in SEQ ID NO: 104 and the amino acid sequence of the light chain is shown in SEQ ID NO: 110.

7 . The PAPPA binding protein of claim 1 , wherein said binding protein inhibits cleavage of IGFBP-2, IGFBP-4 and IGFBP-5.

8 . The PAPPA binding protein of claim 1 , wherein said binding protein binds to human PAPPA with an affinity (KD) of less than 1 nM, wherein affinity (KD) is measured using surface plasmon resonance (SPR) at 25° C. or 37° C.

9 . The PAPPA binding protein of claim 1 , wherein said PAPPA binding protein is a human or humanized PAPPA binding protein.

10 . The PAPPA binding protein of claim 1 , wherein said PAPPA binding protein is an antibody or an antigen binding fragment thereof.

11 . A nucleic acid sequence that encodes a PAPPA binding protein comprising a variable heavy chain (VH) region comprising three heavy chain CDR sequences, CDRH1, CDRH2, and CDRH3, and a variable light chain (VL) region comprising three light chain CDR sequences, CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises SEQ ID NO: 107; CDRH2 comprises SEQ ID NO: 108; CDRH3 comprises SEQ ID NO: 109; CDRL1 comprises SEQ ID NO: 113; CDRL2 comprises SEQ ID NO: 114; and CDRL3 comprises SEQ ID NO: 115.

12 . An expression vector comprising the nucleic acid sequence of claim 11 .

13 . A recombinant host cell comprising the expression vector of claim 12 .

14 . A pharmaceutical composition comprising the PAPPA binding protein of claim 1 and a pharmaceutically acceptable excipient.

15 . A method for the treatment of a polycystic kidney disease (PKD) in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a PAPPA binding protein comprising a variable heavy chain (VH) region comprising three heavy chain CDR sequences, CDRH1, CDRH2, and CDRH3, and a variable light chain (VL) region comprising three light chain CDR sequences, CDRL1, CDRL2, and CDRL3, wherein CDRH1 comprises SEQ ID NO: 107; CDRH2 comprises SEQ ID NO: 108; CDRH3 comprises SEQ ID NO: 109; CDRL1 comprises SEQ ID NO: 113; CDRL2 comprises SEQ ID NO: 114; and CDRL3 comprises SEQ ID NO: 115.

16 . The method of claim 15 wherein the PKD is autosomal dominant PKD (ADPKD).

17 . The method of claim 15 , wherein the VH region comprises an amino acid sequence according to SEQ ID NO: 105 and the VL region comprises an amino acid sequence according to SEQ ID NO: 111.

18 . The method of claim 15 , wherein the PAPPA binding protein comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is shown in SEQ ID NO: 104 and the amino acid sequence of the LC is shown in SEQ ID NO: 110.

19 . The nucleic acid of claim 11 , wherein the VH region comprises an amino acid sequence according to SEQ ID NO: 105 and the VL region comprises an amino acid sequence according to SEQ ID NO: 111.

20 . The nucleic acid of claim 11 , wherein the PAPPA binding protein comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is shown in SEQ ID NO: 104 and the amino acid sequence of the LC is shown in SEQ ID NO: 110.

21 . The PAPPA binding protein of claim 1 , wherein the binding protein binds to an epitope within the M1/M2 region of human PAPPA.

22 . The PAPPA binding protein of claim 21 , wherein said M1/M2 region of human PAPPA corresponds to amino acids 673-1213 of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2026
From: HU, ERDING
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073431/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2026
From: GARDENER, MATTHEW
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073431/0563 →
Continuity (2)
Provisional Application 63651067 · May 23, 2024
Related Publication 20250361323A1 · Nov 27, 2025
References Cited (51)
US 4703039A · Hawiger et al. · 1987 [cited by applicant]
US 5747035A · Presta et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 6180370B1 · Queen · 2001 [cited by examiner]
US 12157776B2 · Freund et al. · 2024 [cited by applicant]
US 20050053973A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050089932A1 · Kolkman et al. · 2005 [cited by applicant]
US 20050164301A1 · Kolkman et al. · 2005 [cited by applicant]
US 20240158534A1 · Freund · 2024 [cited by examiner]
WO WO1986001533 · 1986 [cited by applicant]
WO WO1991014438 · 1991 [cited by applicant]
WO WO1996032478 · 1996 [cited by applicant]
WO WO1997043316 · 1997 [cited by applicant]
WO WO1999043713 · 1999 [cited by applicant]
WO WO2000009560 · 2000 [cited by applicant]
WO WO2000029004 · 2000 [cited by applicant]
WO WO2006130834 · 2006 [cited by applicant]
WO WO2020198166 · 2020 [cited by applicant]
Conover, Cheryl A. “Key questions and answers about pregnancy-associated plasma protein-A.” Trends in endocrinology and metabolism: TEM vol. 23,5 (2012): 242-9. doi:10.1016/j.tem.2012.02.008 (Year: 2012). [cited by examiner]
Janeway, Charles A. “Immunobiology: The Immune System in Health and Disease.” 2001 (Year: 2001). [cited by examiner]
Kipriyanov, Sergey M., and Fabrice Le Gall. “Generation and production of engineered antibodies.” Molecular biotechnology 26.1 (2004): 39-60. (Year: 2004). [cited by examiner]
Aung et al., Autosomal Dominant Polycystic Kidney Disease Prevalence among a Racially Diverse United States Population, 2002 through 2018. Kidney360. Sep. 22, 2021;2(12):2010-2015. [cited by applicant]
Suwabe et al., Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County. Clin J Am Soc Nephrol. Jan. 7, 2020;15(1):69-79. Epub Dec. 2, 2019. [cited by applicant]
Willey et al., Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015. Kidney Dis (Basel). Mar. 2019;5(2):107-117. Epub Jan.… [cited by applicant]
Willey et al., Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States. Curr Med Res Opin. Jul. 2021;37(7):1155-1162. Epub May 25, 2021. [cited by applicant]
Avery et al., Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. Feb./Mar. 2018;10(2):244-255. Epub Jan. 29, 2018. [cited by applicant]
Ratanji et al., Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. Apr.-Jun. 2014;11(2):99-109. Epub Aug. 6, 2013. [cited by applicant]
Judge et al., Structure of the PAPP-ABP5 complex reveals mechanism of substrate recognition. Nat Commun. Sep. 20, 2022;13(1):5500. Erratum in: Nat Commun. Sep. 28, 2022;13(1):5694. [cited by applicant]
Oxvig, C., The role of PAPP-A in the IGF system: location, location, location. J Cell Commun Signal. Jun. 2015;9(2):177-87. Epub Jan. 25, 2015. [cited by applicant]
Mohrin et al., Inhibition of longevity regulator PAPP-A modulates tissue homeostasis via restraint of mesenchymal stromal cells. Aging Cell. Mar. 2021;20(3):e13313. Epub Feb. 9, 2021. [cited by applicant]
Barrios et al., Pregnancy-Associated Plasma Protein (PAPP)-A2 in Physiology and Disease. Cells. Dec. 18, 2021;10(12):3576. [cited by applicant]
Kashyap et al., Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. JCI Insight. Feb. 27, 2020;5(4):e135700. [cited by applicant]
Sharma et al., Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS One. May 30, 2017;12(5):e0178488. [cited by applicant]
Chothia et al., Conformations of immunoglobulin hypervariable regions. Nature. Dec. 21-28, 1989;342(6252):877-83. [cited by applicant]
Tam et al., Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality. Antibodies (Basel). Sep. 1, 2017;6(3):12. [cited by applicant]
Overgaard et al., Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein. Disulfide structure and carbohydrate attachment. J Biol Chem. Jan. 24, 2003;278(4):2106-17. Epub Nov.… [cited by applicant]
Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. Mar. 2001;69(3):89-95. [cited by applicant]
Mikkelsen et al., Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity. Oncotarget. Feb. 28, 2014;5(4):1014-25. [cited by applicant]
Crook et al., Empirical Bayes functional models for hydrogen deuterium exchange mass spectrometry. Commun Biol. Jun. 15, 2022;5(1):588. [cited by applicant]
Laursen et al., Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lette… [cited by applicant]
Atala et al., Juvenile cystic kidneys (jck): a new mouse mutation which causes polycystic kidneys. Kidney Int. May 1993;43(5):1081-5. [cited by applicant]
Natoli et al., Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. Jul. 2010; 16(7):788-92. Epub Jun. 20, 2010. [cited by applicant]
Østergaard et al., Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease. Am J Physiol Renal Physiol. Aug. 1, 2021;321(2):F149-F161. Epub Jun. 28, 2021. [cited by applicant]
Dalbøge et al., Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension—Accelerated Diabetic Kidney Disease. Biomedicines. Jul. 11, 2022;10(7):1661. [cited by applicant]
Loghman-Adham et al., Immortalized epithelial cells from human autosomal dominant polycystic kidney cysts. Am J Physiol Renal Physiol. Sep. 2003;285(3):F397-412. Epub May 6, 2003. [cited by applicant]
Monget et al., Pregnancy-associated plasma protein-A is involved in insulin-like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: identification of cleavage… [cited by applicant]
Dyson et al., Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. Jan.-Dec. 2020;12(1):1829335. [cited by applicant]
Liu et al., High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. Mar.-Apr. 2014;6(2):483-92. Epub Dec. 6, 2013. [cited by applicant]
Mohrin et al., Pharmacological Inhibition of Longevity Regulator PAPP-A Restrains Mesenchymal Stromal Cell Activity. BioRxiv. Feb. 6, 2020. pp. 1-43. [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/EP2025/063798, mailed Aug. 25, 2025, 16 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2025/063798, mailed Oct. 16, 2025, 24 Pages. [cited by applicant]